{"id":"NCT00406783","sponsor":"Organon and Co","briefTitle":"Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)","officialTitle":"Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2006-12-04","resultsPosted":"2009-03-06","lastUpdate":"2024-05-20"},"enrollment":547,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rhinitis, Allergic, Seasonal","Rhinitis, Allergic, Perennial"],"interventions":[{"type":"DRUG","name":"5-mg Desloratadine","otherNames":["SCH 34117, Aerius"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"5-mg Desloratadine tablet","type":"EXPERIMENTAL"},{"label":"Placebo tablet","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis (AR) who meet the criteria for intermittent allergic rhinitis.","primaryOutcome":{"measure":"The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15","timeFrame":"15 days","effectByArm":[{"arm":"5-mg Desloratadine Tablet","deltaMin":-3.01,"sd":0.21},{"arm":"Placebo Tablet","deltaMin":-2.13,"sd":0.2}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19624554"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":276},"commonTop":["Headache"]}}